News

I-Mab will launch a Phase 1 clinical trial evaluating Protollin, its nasal spray immunotherapy candidate for Alzheimer’s disease. The biotech company’s announcement follows the recent approval of an investigational new drug (IND) application for Protollin by the U.S. Food and Drug Administration (FDA). “Advancing Protollin into clinic is…

Phil Frengs is on a coast-to-coast mission to raise money and awareness for Alzheimer’s disease, always thinking of, and honoring, his wife Mimi, who was diagnosed with the condition in November 2013. Frengs, a racing aficionado, is the president and CEO of Legistics, which specializes in document support services…

Note: An update to this story on Aug. 23, 2021, changed the percentage of assisted living facilities that have incorporated personalized music into their care from 3% to 10%, according to corrected information from Dan Cohen.  According to Dan Cohen, founder of the organization Right to Music, about 25,000…

Altoida’s artificial intelligence (AI)-powered device, intended to indicate the start of Alzheimer’s disease in adults with mild dementia but no evident disease symptoms, has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The non-invasive device uses a software that measures and monitors neurocognitive function to…

BIIB080, an investigational therapy for Alzheimer’s disease, was safe and well-tolerated, and sustainably lowered patients’ levels of tau — a protein linked to neurodegeneration, according to topline results of a Phase 1b clinical trial. “There is clearly an urgent need to develop and deliver effective treatments for Alzheimer’s disease,…

A Phase 3 trial testing NE3107, BioVie’s experimental anti-inflammatory insulin-sensitizing therapy, in adults with mild to moderate Alzheimer’s disease has enrolled its first patient. The study, called NM101 (NCT04669028), seeks to enroll up to 316 patients, ages 55–85 years at two sites in Florida. “NE3107 is the…

Treatment with Aduhelm (aducanumab) slows the clinical decline observed in in Alzheimer’s across a range of cognitive and functional measurements, according to a new analysis of data from a Phase 3 clinical trial. The results were presented at the Alzheimer’s Association International Conference (AAIC) 2021, held July 26–30 both…

In clinical trials of the Alzheimer’s treatment Aduhelm (aducanumab), participants who experienced a greater reduction in brain levels of amyloid plaques — the abnormal protein clumps targeted by the treatment — tended to also experience a greater treatment benefit, in terms of cognition and functional ability, according to new…

Most amyloid-related imaging abnormalities (ARIA) occurring in Alzheimer’s patients receiving Aduhelm (aducanumab) are temporary, moderate in severity, and asymptomatic (without symptoms), according to an analysis of data from the Phase 3 ENGAGE and EMERGE trials. Most ARIA-edema (ARIA-E), or fluid accumulation in the brain, occurred within the first eight…

A new center at the Cleveland Clinic in Las Vegas, backed by broadcast journalist Maria Shriver, is focusing its efforts on preventing Alzheimer’s disease in women, who are more at risk of developing the disorder than men. Shriver has been a driving force in recognizing that Alzheimer’s disproportionately affects…